TIDMMTPH

RNS Number : 4457I

Midatech Pharma PLC

14 April 2022

14 April 2022

Midatech Pharma PLC

("Midatech" or the "Company"")

Receipt of NASDAQ Notice

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written notification (the "Notification Letter") from The NASDAQ Stock Market LLC ("NASDAQ"), dated 13 April 2022, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ's rules for continued listing on The NASDAQ Capital Market. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's American Depositary Shares (the "Depositary Shares"), each representing five ordinary shares of the Company, for the 30 consecutive business days beginning 2 March 2022, the Company no longer meets the minimum bid price requirement.

The Notification Letter has no immediate effect on the listing of the Depositary Shares, and they will continue to trade on The NASDAQ Capital Market under the symbol "MTP."

In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, or until 10 October 2022 (the "Compliance Period"), to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Depositary Shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the Compliance Period. If the Depositary Shares do not regain compliance with the minimum bid price requirement during the Compliance Period, the Company may be eligible for an additional grace period of 180 calendar days provided that the Company satisfies NASDAQ's initial listing standards for listing on The NASDAQ Capital Market, other than the minimum bid price requirement, and provides written notice to NASDAQ of its intention to cure the delinquency during the second grace period. If the Company does not regain compliance during the initial grace period and is not eligible for an additional grace period, NASDAQ will provide written notice that the Depositary Shares are subject to delisting from The NASDAQ Capital Market. In that event, the Company may appeal such determination to a hearing panel.

The Company intends to monitor the bid price of its Depositary Shares during the Compliance Period and will consider taking such actions as may be necessary and appropriate to achieve compliance with continued listing requirements prior to the expiration of all available grace periods.

The Company's business operations are not affected by the receipt of the Notification Letter.

The Company's ordinary shares are listed on the AIM Market of the London Stock Exchange, and the Notification Letter does not affect the Company's compliance status with such listing.

For more information, please contact:

 
 Midatech Pharma PLC 
 Stephen Stamp, CEO, CFO 
 Tel: +44 (0)29 2048 0180 
 www.midatechpharma.com 
 
 Strand Hanson Limited (Nominated and Financial Adviser) 
 James Dance / Matthew Chandler / Rob Patrick 
 Tel: +44 (0)20 7409 3494 
 
 Turner Pope Investments (TPI) Limited (Broker) 
 Andrew Thacker / James Pope (Corporate Broking) 
  Tel: +44(0)20 3657 0050 
 
   IFC Advisory Limited (Financial PR and UK Investor Relations) 
 Tim Metcalfe / Graham Herring 
 Tel: +44 (0)20 3934 6630 
 Email: midatech@investor-focus.co.uk 
 
 Edison Group (US Investor Relations) 
  Alyssa Factor 
  Tel: +1 (860) 573 9637 
  Email: afactor@edisongroup.com 
 
 
     About Midatech Pharma PLC 
       Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) 
       is a drug delivery technology company focused on improving the bio-delivery 
       and biodistribution of medicines. The Company combines approved and 
       development medications with its proprietary and innovative drug delivery 
       technologies to provide compelling products that have the potential 
       to powerfully impact the lives of patients. 
 
       The Company has developed three in-house technology platforms, each 
       with its own unique mechanism to improve delivery of medications to 
       sites of disease. All of the Company's technologies have successfully 
       entered human use in the clinic, providing important validation of the 
       potential for each platform: 
        *    Q-Sphera(TM) platform: a disruptive micro-technology 
             used for sustained release to prolong and control the 
             release of therapeutics over an extended period of 
             time (from weeks to months). 
 
 
 
        *    MidaSolve(TM) platform: an innovative nanotechnology 
             used to dissolve insoluble drugs so that they can be 
             administered in liquid form directly and locally into 
             tumours. 
 
 
 
        *    MidaCore(TM) platform: a leading-edge nanotechnology 
             used for targeting medications to sites of disease. 
 
 
 
       The platform nature of the technologies offers the potential to develop 
       multiple drug assets rather than being reliant on a limited number of 
       programmes. Midatech's technologies are supported by 36 patent families 
       including 120 granted patents and an additional 70 patent applications. 
       Midatech's headquarters and R&D facility is in Cardiff, UK. For more 
       information please visit www.midatechpharma.com 
 
  Forward-Looking Statements 
 
  Certain statements in this press release may constitute "forward-looking 
  statements" within the meaning of legislation in the United Kingdom and/or 
  United States Private Securities Litigation Reform Act. Words such as 
  "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," 
  "plan," "may," "will," "could," "should," "believes," "predicts," "potential," 
  "continue," and similar expressions (or the negative versions of such 
  words or expressions) are intended to identify such forward-looking statements. 
  These forward-looking statements include, without limitation, statements 
  expressed or implied regarding Midatech's plans, including those related 
  to Midatech's intentions in response to the Notification Letter, its continued 
  compliance with the NASDAQ Listing Rules, and its intentions during the 
  Compliance Period and after. These forward-looking statements involve 
  significant risks and uncertainties that could cause the actual results 
  to differ materially from those discussed in the forward-looking statements. 
  Most of these factors are outside Midatech's control and are difficult 
  to predict. All statements contained in this press release that do not 
  relate to matters of historical fact should be considered forward-looking 
  statements. 
 
  Reference should be made to those documents that Midatech shall furnish 
  or file from time to time or announcements that may be made by Midatech 
  in accordance with the London Stock Exchange AIM Rules for Companies ("AIM 
  Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules 
  and regulations promulgated by the US Securities and Exchange Commission 
  (the "SEC"), including those risks and uncertainties set forth under "Risk 
  Factors" in Midatech's filings with the SEC, which contains and identifies 
  other important factors that could cause actual results to differ materially 
  from those contained in any projections or forward-looking statements. 
  These forward-looking statements speak only as of the date of this announcement. 
  All subsequent written and oral forward-looking statements by or concerning 
  Midatech are expressly qualified in their entirety by the cautionary statements 
  above. Except as may be required under the AIM Rules or the DTRs or by 
  relevant law in the United Kingdom or the United States, Midatech does 
  not undertake or accept any obligation or undertaking to publicly update 
  or revise any forward-looking statements because of new information, future 
  events or otherwise arising.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSFDFFLEESEDL

(END) Dow Jones Newswires

April 14, 2022 07:37 ET (11:37 GMT)

Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Midatech Pharma Charts.
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Midatech Pharma Charts.